A jury in the first federal trial over transvaginal mesh devices awarded $2 million on Thursday to a woman who alleged that the manufacturer failed to warn about defects in its product that caused her bleeding and pain.
Donna Cisson claims she had to undergo two surgeries to remove the device, one of C.R. Bard Inc.’s line of Avaulta products, which is inserted surgically into women to treat pelvic organ prolaspse – a condition that can cause urinary incontinence or pain, sometimes during sex.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
